669 top medical experts on Membranous Glomerulonephritis across 39 countries and 33 U.S. states, including 582 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Membranous Glomerulonephritis: A type of glomerulonephritis that is characterized by the accumulation of immune deposits (complement membrane attack complex) on the outer aspect of the glomerular basement membrane. It progresses from subepithelial dense deposits, to basement membrane reaction and eventual thickening of the basement membrane.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Glomerulonephritis (2,699), Autoimmune Diseases (3,976).
  4. Clinical Trials ClinicalTrials.gov : at least 69 including 4 Active, 27 Completed, 18 Recruiting
  5. Synonyms: Heymann Nephritis,  Membranous Glomerulopathy,  Membranous Nephropathy


  

        

                    


    These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads, screen scraping or using the data) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

  1. Fervenza, Fernando C   Nephrology   ClinicalTrials.gov Google Publications
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota. Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Disclosed payments in 2021 from 4 biomedical companies, totalling $8,640, including $3,600 from  Otsuka Pharmaceutical Development & Commercialization, Inc.
    Subjects: Glomerulonephritis, Membranous; Receptors, Phospholipase A2; Autoantibodies; Antibodies, Monoclonal, Murine-Derived; Immunoglobulin G; Immunosuppressive Agents
    Categories: Immunology; Therapeutic Use; Drug Therapy; Metabolism; Therapy; Blood
    Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. (2019)
    Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. (2020)

  2. Beck, Laurence H   Nephrology   Google Publications
    Department of Medicine Nephrology, Boston University School of Medicine and Boston Medical Center, Boston, MA, United States.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Relevant US NIH Grant Funding: $874,657 over the last 5 years
    Medical school: Harvard Medical School (MD, 2000)
    Medicare Accepted
    Disclosed payments in 2021 from 3 biomedical companies, totalling $5,770, including $4,800 from  Alexion Pharmaceuticals, Inc.
    Subjects: Glomerulonephritis, Membranous; Receptors, Phospholipase A2; Autoantibodies; Immunoglobulin G; Thrombospondins; Immunosuppressive Agents
    Categories: Immunology; Therapeutic Use; Blood; Diagnosis; Drug Therapy; Complications
    Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. (2014)
    Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy. (2021)

  3. Sethi, Sanjeev   Anatomic Pathology & Clinical Pathology   Google Publications
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota . Top Hospital
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Medical school: Other (MD, 1985)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Disclosed payments from biomedical company (Novartis Pharmaceuticals Corporation) in 2021 for $10,000
    Subjects: Glomerulonephritis, Membranous; Immunosuppressive Agents; Autoantibodies; Immunoglobulin G; Nephritis, Interstitial; Receptors, Phospholipase A2
    Categories: Immunology; Therapeutic Use; Complications; Metabolism; Drug Therapy; Urine
    New 'Antigens' in Membranous Nephropathy. (2021)
    Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. (2019)

  4. Ronco, Pierre   Google Publications
    Sorbonne Université, and Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S1155, Paris, France .
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Glomerulonephritis, Membranous; Receptors, Phospholipase A2; Autoantibodies; Rituximab; Immunoglobulin G; Immunologic Factors
    Categories: Immunology; Blood; Therapeutic Use; Pathology; Diagnosis; Genetics
    Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. (2020)
    Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. (2017)

  5. Salant, David J   Nephrology   Google Publications
    Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
    Physician  Highly Cited  Highly Published  Case Reports 
    Medical school: Other (MD, 1969)
    Medicare Accepted
    Disclosed payments from biomedical company (PFIZER INC.) in 2021 for $1,565
    Subjects: Glomerulonephritis, Membranous; Receptors, Phospholipase A2; Autoantibodies; Immunoglobulin G; Paraneoplastic Syndromes; Thrombospondins
    Categories: Immunology; Blood; Diagnosis; Genetics; Etiology; Pharmacology
    Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. (2014)
    Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy. (2021)

  6. Debiec, Hanna   Google Publications
    Sorbonne Université, and Institut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche S1155, Paris, France.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Glomerulonephritis, Membranous; Receptors, Phospholipase A2; Autoantibodies; Rituximab; Neprilysin; Immunoglobulin G
    Categories: Immunology; Blood; Therapeutic Use; Diagnosis; Genetics; Drug Therapy
    Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. (2020)
    Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. (2017)

  7. Nachman, Patrick H   Nephrology   ClinicalTrials.gov Google Publications
    Division of Renal Diseases and Hypertension, University of Minnesota, Minneapolis, MN, United States. Top Hospital
    Physician  Highly Cited  Highly Published  Case Reports 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 85/100
    Subjects: Glomerulonephritis, Membranous; Venous Thromboembolism; Glomerulonephritis, IGA; Kidney Failure, Chronic; Antibodies, Monoclonal, Murine-Derived; Glomerulosclerosis, Focal Segmental
    Categories: Therapeutic Use; Urine; Epidemiology; Drug Therapy; Pathology; Prevention & Control
    Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. (2019)
    Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. (2010)

  8. Rovin, Brad H   Nephrology   Google Publications
    Division of Nephrology, The Ohio State University, Wexner Medical Center, Columbus, Ohio, USA. Electronic address: . Top Hospital
    Physician  Highly Cited  Clinical Trial 
    Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) (MD, 1983)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 82.3/100
    Disclosed payments in 2021 from 18 biomedical companies, totalling $34,707.44, including $7,540 from  Novartis Pharmaceuticals Corporation
    Subjects: Glomerulonephritis, Membranous; Cyclosporine; Immunosuppressive Agents; Kidney Glomerulus; Rituximab; Disease Progression
    Categories: Therapeutic Use; Drug Therapy; Immunology; Pathology; Therapy; Analysis
    Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. (2019)
    Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. (2019)

  9. Larsen, Christopher P   Anatomic Pathology   Google Publications
    Arkana Laboratories, Little Rock, Arkansas, USA.
    Physician  Highly Cited  Highly Published  Case Reports 
    Relevant US NIH Grant Funding: $548,712 over the last 5 years
    Subjects: Glomerulonephritis, Membranous; Receptors, Phospholipase A2; Autoantibodies; Genetic Predisposition to Disease; Immunoglobulin G; Immunosuppressive Agents
    Categories: Diagnosis; Genetics; Immunology; Pathology; Adverse Effects; Metabolism
    NELL1 is a target antigen in malignancy-associated membranous nephropathy. (2021)
    Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. (2013)

  10. Appel, Gerald B   Nephrology   Google Publications
    Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY. Electronic address: .
    Physician  Highly Cited  Highly Published  Clinical Trial 
    Disclosed payments in 2021 from 63 biomedical companies, totalling $93,797.31, including $40,352.33 from  GlaxoSmithKline, LLC.
    Subjects: Glomerulonephritis, Membranous; Immunosuppressive Agents; Cyclosporine; Glomerulosclerosis, Focal Segmental; Rituximab; Adrenocorticotropic Hormone
    Categories: Therapeutic Use; Drug Therapy; Therapy; Complications; Diagnosis; Drug Effects
    Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. (2019)
    The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. (2020)

  11. Ravindran, Aishwarya   Anatomic Pathology & Clinical Pathology  Google Publications
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Top Hospital
    Physician  Highly Cited 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Subjects: Glomerulonephritis, Membranous; N-Acetylglucosaminyltransferases; Autoantigens; Calcium-Binding Proteins; Glomerular Basement Membrane; Lupus Nephritis
    Categories: Immunology; Metabolism; Pathology
    Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. (2020)
    Exostosin 1/Exostosin 2-Associated Membranous Nephropathy. (2019)

  12. Bomback, Andrew S   Nephrology   Google Publications
    Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY.
    Physician  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Relevant US NIH Grant Funding: $2,304,138 over the last 5 years
    Disclosed payments in 2021 from 10 biomedical companies, totalling $12,733.01, including $4,995 from  Otsuka Pharmaceutical Development & Commercialization, Inc.
    Subjects: Glomerulonephritis, Membranous; Glomerulosclerosis, Focal Segmental; Nephrosis, Lipoid; Communicable Diseases; Glomerulonephritis, IGA; Kidney Glomerulus
    Categories: Epidemiology; Drug Therapy; Genetics; Pathology; Immunology; Therapy
    The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. (2020)
    CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. (2019)

  13. Kiryluk, Krzysztof   Nephrology   Google Publications
    Division of Nephrology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York .
    Physician 
    Relevant US NIH Grant Funding: $5,014,475 over the last 5 years
    Subjects: Glomerulonephritis, Membranous; Genome-Wide Association Study; Glomerulonephritis, IGA; Glomerulosclerosis, Focal Segmental; HLA Antigens; HLA-DQ Antigens
    Categories: Genetics; Pathology; Immunology; Analysis; Diagnosis; Prevention & Control
    The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. (2020)
    CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. (2019)

  14. Gharavi, Ali G   Nephrology  Google Publications
    Department of Medicine, Division of Nephrology, Columbia University, College of Physicians & Surgeons, New York, USA.
    Physician 
    Relevant US NIH Grant Funding: $6,603,259 over the last 5 years
    Medical school: George Washington University School of Medicine (MD, 1990)
    Medicare Accepted
    Disclosed payments in 2021 from 4 biomedical companies, totalling $7,585.49, including $3,858 from  GENZYME CORPORATION
    Subjects: Glomerulonephritis, Membranous; Genome-Wide Association Study; Glomerulonephritis, IGA; Glomerulosclerosis, Focal Segmental; HLA-DQ alpha-Chains; Kidney Failure, Chronic
    Categories: Genetics; Pathology; Diagnosis; Metabolism; Prevention & Control
    The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. (2020)
    CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. (2019)

  15. Cornell, Lynn D   Anatomic Pathology & Clinical Pathology   Google Publications
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Top Hospital
    Physician  Highly Cited  Highly Published  Case Reports 
    Medical school: University of Minnesota Medical School (MD, 2001)
    Medicare Accepted; Medicare MIPS (Merit-based Incentive Payment System) rating: 79.7/100
    Subjects: Glomerulonephritis, Membranous; Immunoglobulin G; Kidney; Nephritis, Interstitial; Alpha-Globulins; Antibodies, Monoclonal, Murine-Derived
    Categories: Immunology; Urine; Epidemiology; Metabolism; Pathology; Therapeutic Use
    In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes. (2021)
    Membranous glomerulonephritis is a manifestation of IgG4-related disease. (2013)

  16. Rizk, Dana V   Nephrology  Google Publications
    Department of Medicine, Division of Nephrology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama. Top Hospital
    Physician  Highly Cited  Clinical Trial 
    Medicare MIPS (Merit-based Incentive Payment System) rating: 72.3/100
    Disclosed payments in 2021 from 5 biomedical companies, totalling $3,973.82, including $2,900 from  Novartis Pharmaceuticals Corporation
    Subjects: Glomerulonephritis, Membranous; Cyclosporine; Immunosuppressive Agents; Rituximab; Glomerulonephritis; Glomerulonephritis, IGA
    Categories: Therapeutic Use; Pathology; Drug Therapy; Prevention & Control
    Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. (2019)
    CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. (2019)

  17. Glassock, Richard J   Nephrology   Google Publications
    Emeritus Professor, Geffen School of Medicine at UCLA, Los Angeles, CA. Electronic address: .
    Physician  Highly Cited  Highly Published  Case Reports 
    Disclosed payments in 2021 from 16 biomedical companies, totalling $20,404.6, including $8,477.8 from  Novartis Pharmaceuticals Corporation
    Subjects: Glomerulonephritis, Membranous; Autoantibodies; Receptors, Phospholipase A2; Anticoagulants; Autoantigens; Cyclophosphamide
    Categories: Immunology; Diagnosis; Etiology; Drug Therapy; Therapeutic Use; Blood
    A Proposal for a Serology-Based Approach to Membranous Nephropathy. (2017)
    The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. (2010)

  18. Waldman, Meryl   Nephrology   ClinicalTrials.gov Google Publications
    Kidney Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
    Physician  Case Reports 
    Subjects: Glomerulonephritis, Membranous; Autoantibodies; Receptors, Phospholipase A2; Blood Component Removal; High-Throughput Screening Assays; Immunoassay
    Categories: Immunology; Blood; Methods; Therapy; Diagnosis; Isolation & Purification
    Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy. (2015)
    Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy. (2020)

  19. Mariani, Laura H   Nephrology   Google Publications
    Department of Medicine, University of Michigan, Ann Arbor, Michigan.
    Physician 
    Relevant US NIH Grant Funding: $3,107,145 over the last 5 years
    Disclosed payments in 2021 from 3 biomedical companies, totalling $4,557.97, including $4,500 from  Travere Therapeutics, Inc.
    Subjects: Glomerulonephritis, Membranous; Communicable Diseases; Glomerulonephritis, IGA; Glomerulosclerosis, Focal Segmental; Nephrosis, Lipoid; Emergency Service, Hospital
    Categories: Epidemiology; Pathology; Diagnosis; Genetics; Prevention & Control; Therapy
    The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. (2020)
    CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. (2019)

  20. Wetzels, Jack F M   ClinicalTrials.gov Google Publications
    Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.
    Scientist  Highly Cited  Highly Published  Clinical Trial  Case Reports 
    Subjects: Glomerulonephritis, Membranous; Receptors, Phospholipase A2; Immunosuppressive Agents; Autoantibodies; Cyclophosphamide; Proteinuria
    Categories: Immunology; Therapeutic Use; Drug Therapy; Urine; Blood; Genetics
    Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. (2019)
    Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. (2011)

Note:
  1. Only the top 20 experts are shown. You may filter your results or use the geolocation tabs. Contact us to purchase the entire list.
These expert listings are for individual use without a fee. Biotechs, Pharmaceuticals, Recruiters, Consultants, Investors, Law firms, and other organizations may use this only for quick evaluations (no downloads or screen scraping) to identify the top medical experts for recruiting, advisory panels, boards, and consulting. Please contact us for licensing, customized queries, feedback and questions.

);